1. Ahlenius, S., Engel, J.: Potentiation by y-methyltyrosine of the suppression of food reinforced lever-pressing behavior induced by anti-psychotic drugs. Acta Pharmacol. Toxicol. 40, 115?125 (1977)
2. Ackenheil, M., Beekmann, H., Greil, W., Hoffmann, G., Markianos, E., Raese, J.: Anti-psychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man. In: The phenothiazines and structurally related drugs, I. S. Forrest, C. J. Carr, and E. Usdin, eds., pp. 647?657. Raven Press, New York 1974
3. Andén, N.-E., Butcher, S. C., Corrodi, H., Fuxe, K., Ungerstedt, U.: Receptor activity and turnover of dopamine and noradrenalin after neuroleptics. Eur. J. Pharmacol. 11, 303?314 (1970)
4. Andén, N.-E., Stock, G.: Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J. Pharm. Pharmacol. 25, 346?348 (1973)
5. Bunney, B., Aghajanian, G.: Anti-psychotic drugs and central dopaminergic neurons. A model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In: Predictability in psychopharmacology: preclinical and clinical correlations. A. Sudilovsky, S. Gershon, and B. Beer, eds., pp. 225?245. New York: Raven Press 1975a